# Ambroxol as a Treatment for Parkinson's Disease Dementia

> **NCT02914366** · PHASE2 · UNKNOWN · sponsor: **London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's** · enrollment: 55 (actual)

## Conditions studied

- Parkinson's Disease Dementia

## Interventions

- **DRUG:** Ambroxol
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02914366
- **Lead sponsor:** London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-11
- **Primary completion:** 2025-12
- **Final completion:** 2025-12
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2024-02-28

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02914366

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02914366, "Ambroxol as a Treatment for Parkinson's Disease Dementia". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02914366. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*